4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

Special dividend estimated to be in range of $1.34 to $1.43 per share Payment of special dividend conditioned upon closing of both Asset Sale and Merger, which are subject to stockholder approval BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX) announced today that its Board of Directors has declared a special dividend in connection with the previously announced asset sale to Janssen Pharmaceutica NV ("Janssen") and merger with Kineta, Inc. ("Kineta"). The special dividend, which the Company estimates will be in range of $1.34 to $1.43 per share of Yumanity common stock, will be payable in cash on or before December 29, 20

BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2022 and provided an overview of the Company's recent corporate developments. Recent Corporate Developments On November 10, 2022, Yumanity announced the effectiveness of a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") in connection with Yumanity's previously announced proposed sale of Yumanity's lead clinical-stage product candidate, YTX-7739, as well as Yumanit

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX) today announced that the registration statement on Form S-4 (the "Registration Statement"), relating to the previously announced asset sale to Janssen Pharmaceutica NV ("Janssen") and merger with Kineta, Inc. ("Kineta"), has been declared effective by the U.S. Securities and Exchange Commission. In June 2022, the Company announced definitive agreements for two strategic transactions. The first definitive agreement is an asset purchase agreement for the sale of Yumanity's lead clinical-stage product candidate, YTX-7739, as well as Yumanity's unpartnered discovery-stage neurosci

BOSTON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity") (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the filing of a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC"). The Registration Statement contains a preliminary proxy statement and prospectus in connection with Yumanity's previously announced proposed asset sale to Janssen Pharmaceutica NV ("Janssen") and merger with Kineta, Inc. ("Kineta"). Although the Registration Statement has not yet

BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2022, and provided an overview of the Company's recent corporate developments. Recent Corporate Developments In June 2022, the Company announced definitive agreements for two strategic transactions. The first definitive agreement is an asset purchase agreement for the sale of Yumanity's lead clinical-stage product candidate, YTX-7739, as well as Yu

Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV in a $26 million cash transaction Kineta, Inc., a private immuno-oncology company, to merge with Yumanity in an all-stock transaction that will advance Kineta's potential best-in-class VISTA blocking immunotherapy The combined company expects to close a PIPE financing in connection with the proposed merger Yumanity and Kineta to host webcast today at 8:30 a.m. EDT BOSTON, June 06, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity") (NASDAQ:YMTX), a clinical-stage biopharmaceutic

YTX-7739 demonstrated target engagement in Phase 1b clinical trial in patients with mild-to-moderate Parkinson's disease YTX-7739 found to be generally well tolerated, demonstrating favorable pharmacokinetic/pharmacodynamic (PK/PD) profiles and a safety profile with no serious adverse events Conference call scheduled for 8:30 a.m. EST, Wednesday, November 10 BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ:YMTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative disease. The Company today reported that its lead product candidate, YTX-7739, in development for

8-K - KINETA, INC./DE (0001445283) (Filer)

8-K - KINETA, INC./DE (0001445283) (Filer)

8-K - KINETA, INC./DE (0001445283) (Filer)

EFFECT - KINETA, INC./DE (0001445283) (Filer)

424B3 - KINETA, INC./DE (0001445283) (Filer)

8-K - KINETA, INC./DE (0001445283) (Filer)

S-3 - KINETA, INC./DE (0001445283) (Filer)

10-Q - KINETA, INC./DE (0001445283) (Filer)

8-K - KINETA, INC./DE (0001445283) (Filer)

8-K - KINETA, INC./DE (0001445283) (Filer)

HC Wainwright & Co. initiated coverage of Yumanity Therapeutics with a rating of Buy and set a new price target of $39.00

Jefferies initiated coverage of Yumanity Therapeutics with a rating of Buy and set a new price target of $35.00

4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

Special dividend estimated to be in range of $1.34 to $1.43 per share Payment of special dividend conditioned upon closing of both Asset Sale and Merger, which are subject to stockholder approval BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX) announced today that its Board of Directors has declared a special dividend in connection with the previously announced asset sale to Janssen Pharmaceutica NV ("Janssen") and merger with Kineta, Inc. ("Kineta"). The special dividend, which the Company estimates will be in range of $1.34 to $1.43 per share of Yumanity common stock, will be payable in cash on or before December 29, 20

BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2022 and provided an overview of the Company's recent corporate developments. Recent Corporate Developments On November 10, 2022, Yumanity announced the effectiveness of a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") in connection with Yumanity's previously announced proposed sale of Yumanity's lead clinical-stage product candidate, YTX-7739, as well as Yumanit

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX) today announced that the registration statement on Form S-4 (the "Registration Statement"), relating to the previously announced asset sale to Janssen Pharmaceutica NV ("Janssen") and merger with Kineta, Inc. ("Kineta"), has been declared effective by the U.S. Securities and Exchange Commission. In June 2022, the Company announced definitive agreements for two strategic transactions. The first definitive agreement is an asset purchase agreement for the sale of Yumanity's lead clinical-stage product candidate, YTX-7739, as well as Yumanity's unpartnered discovery-stage neurosci

BOSTON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity") (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the filing of a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC"). The Registration Statement contains a preliminary proxy statement and prospectus in connection with Yumanity's previously announced proposed asset sale to Janssen Pharmaceutica NV ("Janssen") and merger with Kineta, Inc. ("Kineta"). Although the Registration Statement has not yet

BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2022, and provided an overview of the Company's recent corporate developments. Recent Corporate Developments In June 2022, the Company announced definitive agreements for two strategic transactions. The first definitive agreement is an asset purchase agreement for the sale of Yumanity's lead clinical-stage product candidate, YTX-7739, as well as Yu

Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV in a $26 million cash transaction Kineta, Inc., a private immuno-oncology company, to merge with Yumanity in an all-stock transaction that will advance Kineta's potential best-in-class VISTA blocking immunotherapy The combined company expects to close a PIPE financing in connection with the proposed merger Yumanity and Kineta to host webcast today at 8:30 a.m. EDT BOSTON, June 06, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity") (NASDAQ:YMTX), a clinical-stage biopharmaceutic

BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2022, and provided an overview of the Company's recent corporate developments. Recent Corporate Developments In February 2022, the Company announced its exploration of strategic alternatives to enhance shareholder value and engaged H.C. Wainwright as its exclusive financial advisor to assist in this process. The Company also announced a restructuring of the Company to preserve capital

BOSTON, March 24, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced financial results for full-year ended December 31, 2021 and provided an overview of the Company's recent corporate developments. "We continue to believe in the potential of YTX-7739, which may represent a major advancement in the treatment paradigm for Parkinson's patients," said Richard Peters, M.D., Ph.D., President, Chief Executive Officer and Director of Yumanity. "As previously announced, to preserve capital and optimize shareholder

BOSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative disease, today announced that it is exploring strategic alternatives with the goal of enhancing shareholder value. The Company has engaged H.C. Wainwright as its exclusive financial advisor to assist in this process. Potential strategic alternatives that may be considered as part of this process include an acquisition, merger, reverse merger, other business combination, sales of assets, licensing or other strategic transactions involving the Company. There can be

BOSTON, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the grant to two employees of non-statutory stock options for the purchase of up to an aggregate of 6,000 shares of Yumanity's common stock. The options will vest over four years, with 25 percent of the shares vesting on the first anniversary of the employee's new hire date and the remainder vesting in equal monthly installments over the following three years. The options will have an exercise price of $2.19 per share, which is equal to the

BOSTON, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the appointment of Michael D. Wyzga as Senior Vice President, Chief Financial Officer. "Michael's financial expertise combined with his proven ability to execute strategic and operational objectives will be invaluable to the Company," said Richard Peters, M.D., Ph.D., President, Chief Executive Officer and Director of Yumanity Therapeutics. "We are looking forward to Michael's contributions as we continue to pursue our vision of a future f

BOSTON, June 14, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the appointment of Devin W. Smith as Senior Vice President and General Counsel. "We are delighted to welcome Devin as our general counsel at Yumanity Therapeutics," said Richard Peters, M.D., Ph.D., President, Chief Executive Officer and Director of Yumanity Therapeutics. "His experience providing legal counsel to public emerging life science companies will be important as we advance three clinical programs, move new innovative assets to t

BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ:YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the appointment of Ajay Verma, M.D., Ph.D., as Executive Vice President, Head of Research & Development. Dr. Verma brings more than 25 years of experience developing biotherapeutics in the field of neuroscience. "We are delighted to welcome Dr. Ajay Verma in the newly-created role of Head of R&D at Yumanity Therapeutics," said Richard Peters, M.D., Ph.D., President, Chief Executive Officer and Director of Yumanity Therapeutics. "As a clinically trained neurologist, A

According to Benzinga Pro data, during Q3, Yumanity Therapeutics (NASDAQ:YMTX) posted sales of $1.40 million. Earnings were up 30.59%, but Yumanity Therapeutics still reported an overall loss of $3.36 million. In Q2, Yumanity Therapeutics brought in $1.66 million in sales but lost $4.84 million in earnings. Why Is ROCE Significant? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q3, Yu

Gainers Exact Sciences (NASDAQ:EXAS) shares increased by 17.9% to $52.6 during Friday's pre-market session. The company's market cap stands at $9.3 billion. IMAC Holdings (NASDAQ:BACK) shares increased by 15.71% to $0.28. The company's market cap stands at $9.2 million. Adagene (NASDAQ:ADAG) shares moved upwards by 13.63% to $1.5. The market value of their outstanding shares is at $65.1 million. Monopar Therapeutics (NASDAQ:MNPR) shares moved upwards by 12.45% to $2.98. The market value of their outstanding shares is at $38.3 million. Rezolute (NASDAQ:RZLT) stock rose 10.73% to $1.65. The market value of their outstanding shares is at $60.7 million. Prenetics Global (NASDAQ:PRE) stock

Gainers Scopus BioPharma Inc. (NASDAQ:SCPS) shares rose 74.7% to $0.4104 in pre-market trading after declining 4% on Wednesday. Surrozen, Inc. (NASDAQ:SRZN) shares rose 67.3% to $0.7291 in pre-market trading. The company, last month, posted a narrower Q3 loss. Crown ElectroKinetics Corp. (NASDAQ:CRKN) rose 54.1% to $0.2366 in pre-market trading after gaining 17% on Wednesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. Core Scientific, Inc. (NASDAQ:CORZ) rose 53% to $0.3826 in pre-market trading after B. Riley Financial issued an open letter to Core Scientific shareholders and lenders. Jounce Therapeutics, Inc. (NASDAQ:JNCE) shares rose 23.4% to $0.8499 in

Gainers Crown ElectroKinetics Corp. (NASDAQ:CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) shares jumped 140% to $0.6041 after the company entered into a definitive merger agreement with GRI Bio. Panbela Therapeutics, Inc. (NASDAQ:PBLA) gained 52% to $0.2175. Panbela received EMA opinion on orphan designation for Ivospemin in combination with Gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. Immix Biopharma, Inc. (NASDAQ:IMMX) jumped 46% to $2.1695 after the company announced it has in-licensed BCMA-targeted next-

U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 100 points on Wednesday The Dow traded up 0.42% to 34,252.62 while the NASDAQ rose 0.47% to 11,309.44. The S&P 500 also rose, gaining, 0.47% to 4,038.37. Also check this: Bitcoin Tops $18,000; GMX, Dogecoin Among Top Losers Leading and Lagging Sectors Utilities shares rose by 1.1% on Wednesday. Meanwhile, top gainers in the sector included Genie Energy Ltd. (NYSE:GNE), up 5%, and Cadiz Inc. (NASDAQ:CDZI), up 9%. In trading on Wednesday, energy shares fell by 1%. Top Headline   US import prices fell 0.6% from a month ago in November versus a revised 0.4% drop in the prior month. Export prices decl

U.S. stocks traded higher this morning, with the Dow Jones gaining over 80 points on Wednesday Following the market opening Wednesday, the Dow traded up 0.24% to 34,191.95 while the NASDAQ rose 0.13% to 11,271.20. The S&P 500 also rose, gaining, 0.21% to 4,027.98. Also check this: Bitcoin Tops $18,000; GMX, Dogecoin Among Top Losers Leading and Lagging Sectors Utilities shares rose by 0.8% on Wednesday. Meanwhile, top gainers in the sector included Sunnova Energy International Inc. (NYSE:NOVA), up 4%, and Cadiz Inc. (NASDAQ:CDZI), up 9%. In trading on Wednesday, materials shares fell by 0.3%. Top Headline   US import prices fell 0.6% from a month ago in November versus a revis

Gainers Vallon Pharmaceuticals (NASDAQ:VLON) shares increased by 232.7% to $0.84 during Wednesday's pre-market session. The market value of their outstanding shares is at $10.6 million. Immix Biopharma (NASDAQ:IMMX) stock moved upwards by 45.2% to $2.12. The market value of their outstanding shares is at $29.5 million. Avidity Biosciences (NASDAQ:RNA) stock increased by 34.79% to $14.8. The company's market cap stands at $806.0 million. Kymera Therapeutics (NASDAQ:KYMR) shares moved upwards by 32.95% to $34.37. The market value of their outstanding shares is at $1.8 billion. Fortress Biotech (NASDAQ:FBIO) stock moved upwards by 23.34% to $0.81. The market value of their outstanding shar

Gainers Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) shares rose 150.9% to $0.6313 in pre-market trading after the company entered into a definitive merger agreement with GRI Bio. Crown ElectroKinetics Corp. (NASDAQ:CRKN) shares rose 71.2% to $0.2243 in pre-market trading after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. Versus Systems Inc. (NASDAQ:VS) rose 28% to $1.00 in pre-market trading after gaining around 7% on Tuesday. Versus Systems recently announced pricing of a $2.1 million public offering. Senti Biosciences, Inc. (NASDAQ:SNTI) rose 17.4% to $1.69 in pre-market trading after dipping more than 21% on Tuesday. Scopus BioPharm

Gainers Nymox Pharmaceutical (NASDAQ:NYMX) shares increased by 32.7% to $0.38 during Monday's regular session. As of 12:30 EST, Nymox Pharmaceutical's stock is trading at a volume of 3.2 million, which is 4414.3% of its average full-day volume over the last 100 days. The company's market cap stands at $34.3 million. SCWorx (NASDAQ:WORX) shares moved upwards by 28.95% to $0.72. As of 12:30 EST, SCWorx's stock is trading at a volume of 202.1K, which is 441.6% of its average full-day volume over the last 100 days. The company's market cap stands at $9.4 million. Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 24.87% to $3.01. The current volume of 22.2 million shares is 899.0% of Shuttle P